CSPC Pharmaceutical vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

CSPC Pharmaceutical Group Ltd (1093.HK)

Q3 20262 Jul – 20 Aug 2026

▲4

CSPC's $1.77B AstraZeneca deal and sector tailwinds drive gains

AstraZeneca kidney therapy deal worth up to $1.77B CSPC signed a partnership with AstraZeneca potentially worth $1.77B, including $30M upfront and up to $1.74B in milestones. This validates CSPC's drug platform and brings cash, boosting investor confidence and the stock price.
This is the major new deal directly driving CSPC's outlook and price.
Innovative drug sector rebounds, out-licensing trend strong The innovative drug sector rebounded, with China's out-licensing deals nearing $100B in H1 2026. CSPC's deal is cited as a landmark, signaling strong demand for its technology platforms and supporting higher valuations.
Sector momentum and CSPC's role in the out-licensing trend lift sentiment and demand for the stock.
Pharma sector split: innovative drugs outperform While the broad pharma sector fell 13.6% in H1, innovative drugs bucked the trend. CSPC's $18.5B AstraZeneca deal (total value) highlights its leadership, attracting investors shifting from traditional to innovative pharma.
Shows CSPC benefiting from the rotation into innovative drugs, a key driver of its relative strength.
Moderna cancer vaccine success lifts innovative drug stocks Positive Phase III results for Moderna/Merck's cancer vaccine sent innovative drug stocks surging. CSPC Innovation rose over 10%, as the sector's triple earnings inflection point (commercialization, overseas deals, CXO boom) boosts optimism.
Sector-wide rally on positive clinical news lifts CSPC's stock, reflecting broader demand for innovative drugs.

July 20262 Jul – 20 Aug 2026

▲4

CSPC's $1.77B AstraZeneca deal and sector tailwinds drive gains

AstraZeneca kidney therapy deal worth up to $1.77B CSPC signed a partnership with AstraZeneca potentially worth $1.77B, including $30M upfront and up to $1.74B in milestones. This validates CSPC's drug platform and brings cash, boosting investor confidence and the stock price.
This is the major new deal directly driving CSPC's outlook and price.
Innovative drug sector rebounds, out-licensing trend strong The innovative drug sector rebounded, with China's out-licensing deals nearing $100B in H1 2026. CSPC's deal is cited as a landmark, signaling strong demand for its technology platforms and supporting higher valuations.
Sector momentum and CSPC's role in the out-licensing trend lift sentiment and demand for the stock.
Pharma sector split: innovative drugs outperform While the broad pharma sector fell 13.6% in H1, innovative drugs bucked the trend. CSPC's $18.5B AstraZeneca deal (total value) highlights its leadership, attracting investors shifting from traditional to innovative pharma.
Shows CSPC benefiting from the rotation into innovative drugs, a key driver of its relative strength.
Moderna cancer vaccine success lifts innovative drug stocks Positive Phase III results for Moderna/Merck's cancer vaccine sent innovative drug stocks surging. CSPC Innovation rose over 10%, as the sector's triple earnings inflection point (commercialization, overseas deals, CXO boom) boosts optimism.
Sector-wide rally on positive clinical news lifts CSPC's stock, reflecting broader demand for innovative drugs.

Latest2 Jul – 20 Aug 2026

▲4

CSPC's $1.77B AstraZeneca deal and sector tailwinds drive gains

AstraZeneca kidney therapy deal worth up to $1.77B CSPC signed a partnership with AstraZeneca potentially worth $1.77B, including $30M upfront and up to $1.74B in milestones. This validates CSPC's drug platform and brings cash, boosting investor confidence and the stock price.
This is the major new deal directly driving CSPC's outlook and price.
Innovative drug sector rebounds, out-licensing trend strong The innovative drug sector rebounded, with China's out-licensing deals nearing $100B in H1 2026. CSPC's deal is cited as a landmark, signaling strong demand for its technology platforms and supporting higher valuations.
Sector momentum and CSPC's role in the out-licensing trend lift sentiment and demand for the stock.
Pharma sector split: innovative drugs outperform While the broad pharma sector fell 13.6% in H1, innovative drugs bucked the trend. CSPC's $18.5B AstraZeneca deal (total value) highlights its leadership, attracting investors shifting from traditional to innovative pharma.
Shows CSPC benefiting from the rotation into innovative drugs, a key driver of its relative strength.
Moderna cancer vaccine success lifts innovative drug stocks Positive Phase III results for Moderna/Merck's cancer vaccine sent innovative drug stocks surging. CSPC Innovation rose over 10%, as the sector's triple earnings inflection point (commercialization, overseas deals, CXO boom) boosts optimism.
Sector-wide rally on positive clinical news lifts CSPC's stock, reflecting broader demand for innovative drugs.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.